Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Eastgate Biotech Corp. (ETBI)
Toronto, NV, US
EastGate Biotech Corp. is a pharmaceutical company specializing in the production and distribution of nutraceuticals. These products are rooted in natural therapies and designed for natural absorption within the body. The firm employs cutting-edge nanotechnologies to provide healthier options compared to conventional pharmaceuticals, which often lead to detrimental side effects and unforeseen issues for individuals seeking to achieve and maintain good health. Among its diverse product line are E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze, and Warts X. EastGate Biotech's development process involves integrating product components into various nano-sized delivery systems. These systems include oil droplets (nanoemulsions), polymeric particles (nanoparticles), and complex combinations of polymers, lipids, and surfactants (such as hybrid nanoparticles, nanocapsules, and mixed micelles). The company has operational bases in prominent cities including New York, London SF, Cockfosters BP, Los Angeles, Chicago, and Las Vegas.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +200.00% | +200.00% | +0.00% | +0.00% | -25.00% | +36.36% | +50.00% | -87.76% | -98.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Pharmaceuticals: +7.8%-26.7% Q3'17: +1,269.9% (vs Q3'16)
-
EPS growth Medical - Pharmaceuticals: +20.2%-58.3% Q3'17: +34.8% (vs Q3'16)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-2,141.8% Q3'17: -5,750.7% (vs Q3'16)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-3,282.4% Q3'17: -7,439.6% (vs Q3'16)
-
ROIC Medical - Pharmaceuticals: +6.1%— Q3'17: +305.3% (vs Q3'16)
-
Share dilution Medical - Pharmaceuticals: +0.0%+49.5% Q3'17: +262.4% (vs Q3'16)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-1.45× Q3'17: -0.45× (vs Q3'16)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2015-01-15 | PERRI ROSE C | Officer | — | D | Common Shares | 0 | 0.00 | — | 5,395,519 | — | ↗ |
| 2015-01-05 | PERRI ROSE C | Officer | — | D | Warrant | 1,036,475 | 0.04 | 41.5K | 0 | — | ↗ |
| 2015-01-05 | GLUSKIN ANNA E | Director | P-Purchase | A | WARRANT | 1,243,750 | 0.04 | 49.8K | 2,251,750 | — | ↗ |
| 2014-11-09 | PERRI ROSE C | Officer | — | D | Warrant | 320,400 | 0.25 | 80.1K | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joseph Schwarz | Chief Scientific Officer | — | — |
| Rosella C. Perri | Chief Executive Officer, Secretary, Treasurer & Director | — | female |
| William D. Abajian | Vice Chairman, President & Chief Operating Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ETBI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
